Nanoparticle-based targeted gene therapy for lung cancer

American Journal of Cancer Research

Volumn 6, Issue 5, 2016, Pages 1118-1134

  Lee, Hung Yen ^a   Mohammed, Kamal A ^a,b   Nasreen, Najmunnisa ^a,b  

^a The College of Medicine   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

EphA2; EphrinA1; Lung cancer; Malignant mesothelioma; Nanoparticles; Targeted gene therapy

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; AFATINIB; ALGINIC ACID; BEVACIZUMAB; CHITOSAN; CISPLATIN; DENDRIMER; EPHRIN A1; EPHRIN A2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GONADORELIN DERIVATIVE; HYALURONIC ACID; LIPOSOME; MACROGOL; METAL NANOPARTICLE; NANOPARTICLE; POLYCAPROLACTONE; POLYETHYLENEIMINE; POLYGLACTIN; POLYMER; RAMUCIRUMAB; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CANCER CELL; CANCER GENE THERAPY; CANCER PATIENT; CONTROLLED RELEASE FORMULATION; DNA SEQUENCE; ENCAPSULATION; HUMAN; HYDROPHOBICITY; LUNG CANCER; LUNG SURGERY; METASTASIS INHIBITION; MICELLE; NON SMALL CELL LUNG CANCER; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLEURA MESOTHELIOMA; RNA SEQUENCE;

EID: 84992497277     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (104)

1. Lee HY, Mohammed KA, Kaye F, Sharma P, Moudgil BM, Clapp WL and Nasreen N. Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer. International Journal of Nanomedicine 2013; 8: 4481-4493.
2. Khodayari N, Mohammed KA, Goldberg EP and Nasreen N. EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene. Cancer Gene Ther 2011; 18: 806-816.
3. Nasreen N, Khodayari N and Mohammed KA. Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach. Am J Cancer Res 2012; 2: 222-234.
4. American cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016.
5. Dungo RT and Keating GM. Afatinib: First Global Approval. Drugs 2013; 73: 1503-1515.
6. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu YZ, Liepa AM, Gao L, Schwartz JD, Tabernero J and Investigators RT. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39.
7. Molina JR, Yang PG, Cassivi SD, Schild SE and Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proceedings 2008; 83: 584-594.
8. Nelson V, Ziehr J, Agulnik M and Johnson M. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Oncotargets and Therapy 2013; 6: 135-143.
9. Popat S, Mok T, Yang JCH, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T and Paz-Ares L. Afatinib in the treatment of EGFR mutation-positive NSCLC A network meta-analysis. Lung Cancer 2014; 85: 230-238.
10. Kasinski AL and Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nature Reviews Cancer 2011; 11: 849-864.
11. Downward J. Targeting ras signalling pathways in cancer therapy. Nature Reviews Cancer 2003; 3: 11-22.
12. Sharma SV, Bell DW, Settleman J and Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer 2007; 7: 169-181.
13. Maeda H, Wu J, Sawa T, Matsumura Y and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-284.
14. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189-207.
15. Alexis F, Pridgen E, Molnar LK and Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmaceutics 2008; 5: 505-515.
16. Albanese A, Tang PS and Chan WCW. The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems. Annu Rev Biomed Eng 2012; 14: 1-16.
17. Byrne JD, Betancourt T and Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Advanced Drug Delivery Reviews 2008; 60: 1615-1626.
18. Karra N and Benita S. The Ligand Nanoparticle Conjugation Approach for Targeted Cancer Therapy. Current Drug Metabolism 2012; 13: 22-41.
19. Bazak R, Houri M, El Achy S, Kamel S and Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol 2015; 141: 769-784.
20. Pirollo KF and Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends in Biotechnology 2008; 26: 552-558.
21. Xu S, Olenyuk BZ, Okamoto CT and Hamm-Alvarez SF. Targeting receptor-mediated endocytotic pathways with nanoparticles: Rationale and advances. Advanced Drug Delivery Reviews 2013; 65: 121-138.
22. Yameen B, Choi WI, Vilos C, Swami A, Shi JJ and Farokhzad OC. Insight into nanoparticle cellular uptake and intracellular targeting. Journal of Controlled Release 2014; 190: 485-499.
23. Endres TK, Beck-Broichsitter M, Samsonova O, Renette T and Kissel TH. Self-assembled biodegradable amphiphilic PEG-PCL-lPEI triblock copolymers at the borderline between micelles and nanoparticles designed for drug and gene delivery. Biomaterials 2011; 32: 7721-7731.
24. Sun TM, Du JZ, Yan LF, Mao HQ and Wang J. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery. Biomaterials 2008; 29: 4348-4355.
25. Karimi M, Avci P, Mobasseri R, Hamblin MR and Naderi-Manesh H. The novel albumin-chitosan core-shell nanoparticles for gene delivery: preparation, optimization and cell uptake investigation. J Nanopart Res 2013; 15: 1651.
26. Jang JS, Kim SY, Lee SB, Kim KO, Han JS and Lee YM. Poly(ethylene glycol)/poly(epsilon-caprolactone) diblock copolymeric nanoparticles for non-viral gene delivery: the role of charge group and molecular weight in particle formation, cytotoxicity and transfection. J Control Release 2006; 113: 173-182.
27. Wang K, Kievit FM, Florczyk SJ, Stephen ZR and Zhang M. 3D Porous Chitosan-Alginate Scaffolds as an In Vitro Model for Evaluating Nanoparticle-Mediated Tumor Targeting and Gene Delivery to Prostate Cancer. Biomacromolecules 2015; 16: 3362-3372.
28. Young TJ, Johnson KP, Pace GW and Mishra AK. Phospholipid-stabilized nanoparticles of cyclosporine A by rapid expansion from supercritical to aqueous solution. Aaps Pharmscitech 2004; 5: E11.
29. Su WP, Cheng FY, Shieh DB, Yeh CS and Su WC. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine 2012; 7: 4269-4283.
30. Bordelon H, Biris AS, Sabliov CM and Monroe WT. Characterization of Plasmid DNA Location within Chitosan/PLGA/pDNA Nanoparticle Complexes Designed for Gene Delivery. Journal of Nanomaterials 2011.
31. Endres TK, Beck-Broichsitter M, Samsonova O, Renette T and Kissel TH. Self-assembled biodegradable amphiphilic PEG-PCL-lPEI triblock copolymers at the borderline between micelles and nanoparticles designed for drug and gene delivery. Biomaterials 2011; 32: 7721-7731.
32. Sun TM, Du JZ, Yan LF, Mao HQ and Wang J. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery. Biomaterials 2008; 29: 4348-4355.
33. Jang JS, Kim SY, Lee SB, Kim KO, Han JS and Lee YM. Poly(ethylene glycol)/poly(epsilon-caprolactone) diblock copolymeric nanoparticles for non-viral gene delivery: The role of charge group and molecular weight in particle formation, cytotoxicity and transfection. Journal of Controlled Release 2006; 113: 173-182.
34. You JO and Peng CA. Calcium-alginate nanoparticles formed by reverse microemulsion as gene carriers. Macromolecular Symposia 2004; 219: 147-153.
35. Su WP, Cheng FY, Shieh DB, Yeh CS and Su WC. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine 2012; 7: 4269-4283.
36. Liu YL, Wu YH, Tsai WB, Tsai CC, Chen WS and Wu CS. Core-shell silica@chitosan nanoparticles and hollow chitosan nanospheres using silica nanoparticles as templates: Preparation and ultrasound bubble application. Carbohydrate Polymers 2011; 84: 770-774.
37. Ma X, Zhao Y, Ng KW and Zhao YL. Integrated Hollow Mesoporous Silica Nanoparticles for Target Drug/siRNA Co-Delivery. Chemistry-a European Journal 2013; 19: 15593-15603.
38. Liu CH and Yu SY. Cationic nanoemulsions as non-viral vectors for plasmid DNA delivery. Colloids Surf B Biointerfaces 2010; 79: 509-515.
39. Cai LL, Wang XH, Wang WW, Qiu N, Wen JL, Duan XM, Li X, Chen X, Yang L, Qian ZY, Wei YQ and Chen LJ. Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo. Int J Nanomedicine 2012; 7: 4499-4510.
40. Kibria G, Hatakeyama H, Ohga N, Hida K and Harashima H. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release 2011; 153: 141-148.
41. Muthiah M, Park IK and Cho CS. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics. Expert Opinion on Drug Delivery 2013; 10: 1259-1273.
42. Tong AW. Small RNAs and non-small cell lung cancer. Curr Mol Med 2006; 6: 339-349.
43. Zou S, Scarfo K, Nantz MH and Hecker JG. Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells. Int J Pharm 2010; 389: 232-243.
44. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM and Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 1987; 84: 7413-7.
45. Wasungu L and Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. J Control Release 2006; 116: 255-264.
46. Ma BC, Zhang SB, Jiang HM, Zhao BD and Lv HT. Lipoplex morphologies and their influences on transfection efficiency in gene delivery. J Control Release 2007; 123: 184-194.
47. Qu MH, Zeng RF, Fang S, Dai QS, Li HP and Long JT. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Int J Pharm 2014; 474: 112-122.
48. Lei H, Hofferberth SC, Liu R, Colby A, Tevis KM, Catalano P, Grinstaff MW and Colson YL. Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids. J Thorac Cardiovasc Surg 2015; 149: 1417-1424; discussion 1424-1425 e1411.
49. Mayol L, Serri C, Menale C, Crispi S, Piccolo MT, Mita L, Giarra S, Forte M, Saija A, Biondi M and Mita DG. Curcumin loaded PLGA-poloxamer blend nanoparticles induce cell cycle arrest in mesothelioma cells. Eur J Pharm Biopharm 2015; 93: 37-45.
50. Kanai O, Fujita K, Nakatani K and Mio T. Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma. Respirol Case Rep 2016; 4: 28-31.
51. Iyer AK, Su Y, Feng J, Lan X, Zhu X, Liu Y, Gao D, Seo Y, Vanbrocklin HF, Courtney Broaddus V, Liu B and He J. The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. Biomaterials 2011; 32: 2605-2613.
52. Nimesh S. Polyethylenimine as a promising vector for targeted siRNA delivery. Current clinical pharmacology 2012; 7: 121-130.
53. Patnaik S and Gupta KC. Novel polyethylenimine-derived nanoparticles for in vivo gene delivery. Expert Opin Drug Deliv 2013; 10: 215-228.
54. Kafil V and Omidi Y. Cytotoxic impacts of linear and branched polyethylenimine nanostructures in a431 cells. BioImpacts: BI 2011; 1: 23-30.
55. Zamora-Avila DE, Zapata-Benavides P, Franco-Molina MA, Saavedra-Alonso S, Trejo-Avila LM, Resendez-Perez D, Mendez-Vazquez JL, Isaias-Badillo J and Rodriguez-Padilla C. WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Therapy 2009; 16: 892-899.
56. Bonnet ME, Gossart JB, Benoit E, Messmer M, Zounib O, Moreau V, Behr JP, Lenne-Samuel N, Kedinger V, Meulle A, Erbacher P and Bolcato-Bellemin AL. Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition. J Control Release 2013; 170: 183-190.
57. Chen S, Liu XX, Gong WF, Yang H, Luo DF, Zuo XL, Li WS, Wu P, Liu L, Xu Q and Ji AM. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts. Oncol Rep 2013; 29: 260-268.
58. Guo GY, Zhou L, Chen ZF, Chi WL, Yang XQ, Wang W and Zhang BL. Alkane-modified low-molecular-weight polyethylenimine with enhanced gene silencing for siRNA delivery. Int J Pharm 2013; 450: 44-52.
59. Ganesh S, Iyer AK, Morrissey DV and Amiji MM. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 2013; 34: 3489-3502.
60. Li X, Chen YJ, Wang MQ, Ma YJ, Xia WL and Gu HC. A mesoporous silica nanoparticle PEI Fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials 2013; 34: 1391-1401.
61. Bai SH, Thomas C, Rawat A and Ahsan F. Recent progress in dendrimer-based nanocarriers. Criti Rev Ther Drug Carrier Syst 2006; 23: 437-495.
62. Shcharbin D, Shakhbazau A and Bryszewska M. Poly(amidoamine) dendrimer complexes as a platform for gene delivery. Expert Opinion on Drug Delivery 2013; 10: 1687-1698.
63. Kesharwani P and Lyer AK. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discovery Today 2015; 20: 536-547.
64. Pack DW, Hoffman AS, Pun S and Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005; 4: 581-593.
65. Taratula O, Garbuzenko OB, Kirkpatrick P, Pandya I, Savla R, Pozharov VP, He H and Minko T. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release 2009; 140: 284-293.
66. Wang H, Zhao X, Guo C, Ren D, Zhao Y, Xiao W and Jiao W. Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells. PLoS One 2015; 10: e0139136.
67. Liu XQ, Sun CY, Yang XZ and Wang J. Polymeric-Micelle-Based Nanomedicine for siRNA Delivery. Particle & Particle Systems Characterization 2013; 30: 211-228.
68. Jhaveri AM and Torchilin VP. Multifunctional polymeric micelles for delivery of drugs and siRNA. Front Pharmacol 2014; 5: 77.
69. Navarro G, Pan JY and Torchilin VP. Micelle-like Nanoparticles as Carriers for DNA and siRNA. Molecular Pharmaceutics 2015; 12: 301-313.
70. Gong J, Chen MW, Zheng Y, Wang SP and Wang YT. Polymeric micelles drug delivery system in oncology. J Control Release 2012; 159: 312-323.
71. Cabral H and Kataoka K. Progress of drug-loaded polymeric micelles into clinical studies. J Control Release 2014; 190: 465-476.
72. Shen JA, Yin Q, Chen LL, Zhang ZW and Li YP. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 2012; 33: 8613-8624.
73. Shen JA, Sun HP, Xu PF, Yin Q, Zhang ZW, Wang SL, Yu HJ and Li YP. Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles. Biomaterials 2013; 34: 1581-1590.
74. Hao SH, Yan Y, Ren X, Xu Y, Chen LL and Zhang HB. Candesartan-graft-polyethyleneimine Cationic Micelles for Effective Co-delivery of Drug and Gene in Anti-angiogenic Lung Cancer Ther apy. Biotechnology and Bioprocess Engineering 2015; 20: 550-560.
75. Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch CD, Xu K, Atkinson EN, Bekele BN, Stephens LC, Minna JD, Roth JA and Ramesh R. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Therapy 2004; 11: 733-739.
76. Landen CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G and Sood AK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005; 65: 6910-6918.
77. Zhu X, Xu YJ, Solis LM, Tao W, Wang LZ, Behrens C, Xu XY, Zhao LL, Liu D, Wu J, Zhang N, Wistuba, II, Farokhzad OC, Zetter BR and Shi JJ. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci U S A 2015; 112: 7779-7784.
78. Hattori Y, Yamasaku H and Maitani Y. Anionic polymer-coated lipoplex for safe gene delivery into tumor by systemic injection. J Drug Target 2013; 21: 639-647.
79. Li P, Liu D, Sun X, Liu C, Liu Y and Zhang N. A novel cationic liposome formulation for efficient gene delivery via a pulmonary route. Nanotechnology 2011; 22: 245104.
80. Lee RJ and Huang L. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J Biol Chem 1996; 271: 8481-8487.
81. Patil SD, Rhodes DG and Burgess DJ. Anionic liposomal delivery system for DNA transfection. AAPS J 2004; 6: e29.
82. Kapoor M and Burgess DJ. Physicochemical characterization of anionic lipid-based ternary siRNA complexes. Biochim Biophys Acta 2012; 1818: 1603-1612.
83. Krasnici S, Werner A, Eichhorn ME, Schmitt-Sody M, Pahernik SA, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K and Dellian M. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003; 105: 561-7.
84. Targeted SiRNA Delivery Using A Novel Anionic Lipid/Polyhedral Oligomeric Silsesquioxane Complex System For Malignant Pleural Mesothelioma. Am J Respir Crit Care Med 2015;191: A1123.
85. Das S and Chaudhury A. Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery. AAPS PharmSciTech 2011; 12: 62-76.
86. Bummer PM. Physical chemical considerations of lipid-based oral drug delivery Solid lipid nanoparticles. Crit Rev Ther Drug Carrier Syst 2004; 21: 1-19.
87. Delgado D, del Pozo-Rodriguez A, Angeles Solinis M, Bartkowiak A and Rodriguez-Gascon A. New gene delivery system based on oligochitosan and solid lipid nanoparticles: 'In vitro' and 'in vivo' evaluation. Eur J Pharm Sci 2013; 50: 484-491.
88. He S-N, Li YL, Yan JJ, Zhang W, Du YZ, Yu HY, Hu FQ and Yuan H. Ternary nanoparticles composed of cationic solid lipid nanoparticles, protamine, and DNA for gene delivery. Int J Nanomedicine 2013; 8: 2859-2869.
89. Delgado D, Gascon AR, del Pozo-Rodriguez A, Echevarria E, de Garibay APR, Rodriguez JM and Solinis MA. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: In vitro characterization and in vivo transfection after intravenous administration to mice. Int J Pharm 2012; 425: 35-43.
90. Choi SH, Jin SE, Lee MK, Lim SJ, Park JS, Kim BG, Ahn WS and Kim CK. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur J Pharm Biopharm 2008; 68: 545-554.
91. Han Y, Zhang P, Chen Y, Sun J and Kong F. Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy. Int J Mol Med 2014; 34: 191-196.
92. Mieszawska AJ, Mulder WJ, Fayad ZA and Cormode DP. Multifunctional Gold Nanoparticles for Diagnosis and Therapy of Disease. Mol Pharm 2013; 10: 831-847.
93. Lajunen T, Viitala L, Kontturi LS, Laaksonen T, Liang H, Vuorimaa-Laukkanen E, Viitala T, Le Guevel X, Yliperttula M, Murtomaki L and Urtti A. Light induced cytosolic drug delivery from liposomes with gold nanoparticles. J Control Release 2015; 203: 85-98.
94. Ding Y, Jiang Z, Saha K, Kim CS, Kim ST, Landis RF and Rotello VM. Gold Nanoparticles for Nucleic Acid Delivery. Mol Ther 2014; 22: 1075-1083.
95. Tiwari PK and Lee YS. Gene delivery in conjunction with gold nanoparticle and tumor treating electric field. J Applied Physics 2013; 114.
96. Ryou SM, Kim S, Jang HH, Kim JH, Yeom JH, Eom MS, Bae J, Han MS and Lee K. Delivery of shRNA using gold nanoparticle-DNA oligonucleotide conjugates as a universal carrier. Biochem Biophys Res Commun 2010; 398: 542-546.
97. Bishop CJ, Tzeng SY and Green JJ. Degradable polymer-coated gold nanoparticles for co-delivery of DNA and siRNA. Acta Biomater 2015; 11: 393-403.
98. Shan Y, Luo T, Peng C, Sheng R, Cao A, Cao X, Shen M, Guo R, Tomas H and Shi X. Gene deliv ery using dendrimer-entrapped gold nanoparticles as nonviral vectors. Biomaterials 2012; 33: 3025-3035.
99. Guo S, Huang Y, Jiang Q, Sun Y, Deng L, Liang Z, Du Q, Xing J, Zhao Y, Wang PC, Dong A and Liang XJ. Enhanced Gene Delivery and siRNA Silencing by Gold Nanoparticles Coated with Charge-Reversal Polyelectrolyte. ACS Nano 2010; 4: 5505-5511.
100. Conde J, Tian F, Hernandez Y, Bao C, Cui D, Janssen KP, Ricardo Ibarra M, Baptista PV, Stoeger T and de la Fuente JM. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials 2013; 34: 7744-7753.
101. Choi SJ, Oh JM and Choy JH. Toxicological effects of inorganic nanoparticles on human lung cancer A549 cells. J Inorg Biochem 2009; 103: 463-471.
102. Wang C, Ravi S, Martinez GV, Chinnasamy V, Raulji P, Howell M, Davis Y, Mallela J, Seehra MS and Mohapatra S. Dual-purpose magnetic micelles for MRI and gene delivery. J Control Release 2012; 163: 82-92.
103. Jiang S, Eltoukhy AA, Love KT, Langer R and Anderson DG. Lipidoid-Coated Iron Oxide Nanoparticles for Efficient DNA and siRNA delivery. Nano Lett 2013; 13: 1059-1064.
104. Li Z, Xiang J, Zhang W, Fan S, Wu M, Li X and Li G. Nanoparticle delivery of anti-metastatic NM23-H1 gene improves chemotherapy in a mouse tumor model. Cancer Gene Ther 2009; 16: 423-429.